Discovery of a novel series of quinolone α7 nicotinic acetylcholine receptor agonists

Bioorganic and Medicinal Chemistry Letters

Volumn 23, Issue 6, 2013, Pages 1684-1688

  McDonald, Ivar M ^a   Mate, Robert A ^a   Zusi, F Christopher ^a   Huang, Hong ^a   Post Munson, Debra J ^a   Ferrante, Meredith A ^a   Gallagher, Lizbeth ^a   Bertekap Jr , Robert L ^a   Knox, Ronald J ^a   Robertson, Barbara J ^a   Harden, David G ^a   Morgan, Daniel G ^a   Lodge, Nicholas J ^a   Dworetzky, Steven I ^a   Olson, Richard E ^a   MacOr, John E ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

7 Nicotinic acetylcholine receptor; Basicity; Efflux; Schizophrenia

Indexed keywords

4 PHENYL 1 (QUINUCLIDIN 3 YLMETHYL)QUINOLIN 2(1H) ONE; NICOTINIC AGENT; QUINOLONE DERIVATIVE; QUINUCLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG PENETRATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG TRANSPORT; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; KNOEVENAGEL CONDENSATION; PENETRANCE; SCHIZOPHRENIA; SUPERCRITICAL FLUID CHROMATOGRAPHY; SUZUKI REACTION;

ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR; ANIMALS; CACO-2 CELLS; DRUG EVALUATION, PRECLINICAL; HUMANS; KINETICS; NICOTINIC AGONISTS; QUINOLONES; RATS; RECEPTORS, NICOTINIC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84874656390     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2013.01.070     Document Type: Article

References (17)

1. M. Hajos, and B.N. Rogers Curr. Pharm. Des. 16 2010 538
2. T.L. Wallace, and R.H.P. Porter Biochem. Pharmacol. 82 2011 891
3. A.A. Mazurov, J.D. Speake, and D. Yohannes J. Med. Chem. 54 2011 7943
4. M.B. Marrero, M. Bencherif, P.M. Lippiello, and R. Lucas Pharm. Res. 2011 413
5. For EVP-6124, see: J. Prickaerts, N.P. van Goethem, R. Chesworth, G. Shapiro, F.G. Boess, C. Methfessel, O.A.H. Reneerkens, D.G. Flood, D. Hilt, M. Gawryl, S. Bertrand, D. Bertrand, and D. König Neuropharmacology 1099 2012
6. For AZD0328, see: S. Sydserff, E.J. Sutton, D. Song, M.C. Quirk, C. Maciag, C. Li, G. Jonak, D. Gurley, J.C. Gordon, E.P. Christian, J.J. Doherty, T. Hudzik, E. Johnson, L. Mrzljak, T. Piser, G.N. Smagin, Y. Wang, D. Widzowski, and J.S. Smith Biochem. Pharmacol. 78 2009 880
7. For GTS-21, see: H. Kitagawa, T. Takenouchi, R. Azuma, K.A. Wesnes, W.G. Kramer, D.E. Clody, and A.L. Burnett Neuropsychopharmacology 2003 542
8. R. Rudolf, M. Mongillo, R. Rizzuto, and T. Pozzan Nat. Rev. Mol. Cell Biol. 4 2003 579
9. J.E. González, and M.P. Maher Receptors Channels 8 2002 283
10. For a recent example of a series of α7 nAChR agonists with longer tethers between the amine and carbonyl moieties, see: R. Zanaletti, L. Bettinetti, C. Castaldo, G. Cocconcelli, T. Comrey, J. Dunlop, G. Gaviraghi, C. Ghiron, S.N. Haydar, F. Jow, L. Maccari, I. Micco, A. Nencini, C. Scali, E. Turlizzi, and M. Valacchi J. Med. Chem. 2012 4806
11. Turk, C. F.; Krapcho, J. U.S. Patent 4,232,027, 1980.
12. K.Y. Koltunov, S. Walspurger, and J. Sommer Eur. J. Org. Chem. 19 2004 4039
13. max data is not reported. For more background on the relationship between FLIPR and EP data, see: J. Dunlop, R. Roncarti, B. Jow, H. Bothman, T. Lock, D. Kowal, M. Bowlby, and G.C. Terstappen Biochem. Pharmacol. 74 2007 1172
14. P.L. Stotter, M.D. Friedman, G.O. Dorsey, R.W. Shiely, R.F. Williams, and D.E. Minter Heterocycles 25 1987 251
15. R.L. Papke, and J.K. Porter-Papke Br. J. Pharmacol. 137 2002 49
16. G. Ecker, M. Huber, D. Schmid, and P. Chiba Mol. Pharmacol. 1999 791
17. For a similar approach to mitigating PGP efflux by tempering amine basicity via the installation of proximal fluorine atoms, see: C.D. Cox, M.J. Breslin, D.B. Whitman, P.J. Coleman, R.M. Garbaccio, M.E. Fraley, M.M. Zrada, C.A. Buser, E.S. Walsh, K. Hamilton, R.B. Lobell, W. Tao, M.T. Abrams, V.J. South, H.E. Huber, N.E. Kohl, and G.D. Hartman Bioorg. Med. Chem. Lett. 2007 2697